Journal of Experimental & Clinical Medicine
Volume 4, Issue 1 , Pages 14-19 , February 2012

New Insights into the Pathogenesis and Treatment of Patients with Immunoglobulin A Nephropathy

  • Yasuhiko Tomino

      Affiliations

    • Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
    • Juntendo University International Center (JUIC), Tokyo, Japan
    • Corresponding Author InformationDivision of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 813-8421, Japan.

Received 3 August 2011 ,Revised 23 September 2011 ,Accepted 23 September 2011.

References 

  1. Berger J, Hinglais N. Les Depots intercapillaries d’IgA-IgG. J Urol Nephrol. 1968;74:694–695
  2. Nakayama K, Ohsawa I, Maeda-Ohtani A, Murakoshi M, Horikoshi S, Tomino Y. Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal. 2008;22:114–118
  3. Maeda A, Gohda T, Funabiki K, Horikoshi S, Shirato I, Tomino Y. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal. 2003;17:73–76
  4. Koyama A, Igarashi M, Kobayshi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research group on progressive renal diseases. Am J Kidney Dis. 1997;29:526–532
  5. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–3074
  6. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–545
  7. Tomino Y. IgA nephropathy: lessons from an animal model, the ddY mouse. J Nephrol. 2008;21:464–467
  8. Imai H, Nakamoto Y, Asakura K, Miki K, Yasuda T, Miura AB. Spontaneous glomerular IgA deposition in ddY mice: An animal model of IgA nephritis. Kidney Int. 1985;27:756–761
  9. Suzuki H, Suzuki Y, Yamanaka T, Hirose S, Nishimura H, Toei J, et al Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10 in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol. 2005;16:1289–1299
  10. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, et al IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6Q22-23. Nat Genet. 2000;26:354–357
  11. Tomino Y, Endoh M, Nomoto Y, Sakai H. IgA1 and IgA nephropathy. N Engl J Med. 1981;305:1159–1160
  12. Oortwijn BD, van der Boog PJ, Roos A, van der Greest RN, de Filter JW, Daha MR, et al. A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int. 2006;69:1131–1138
  13. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, et al Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19:2384–2395
  14. Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, et al Th1 polarization in murine IgA nephropathy directed by bone-marrow-derived cells. Kidney Int. 2007;72:319–327
  15. Suzuki H, Moldveanu Z, Hall S, Brown R, Vu HL, Novak L, et al IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629–639
  16. Qin W, Zhou Q, Yang LC, Li Z, Su BH, Luo H, et al. Peripheral B lymphocyte beta-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med. 2005;258:467–477
  17. Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol. 1998;9:2048–2054
  18. Yan Y, Xu LX, Zhang JJ, Zhang Y, Zhao MH. Self-aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy. Clin Exp Immunol. 2006;144:17–24
  19. Bonner A, Furtado PB, Almogren A, Kerr MA, Perkins SJ. Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy. J Immunol. 2008;180:1008–1018
  20. van der Boog PJ, van Kooten C, de Fijter JW, Daha MR. Role of macromolecular IgA in IgA nephropathy. Kidney Int. 2005;67:813–821
  21. Tomino Y. Pathogenesis of IgA nephropathy. IgA nephropathy today In:  Tomino Y editors. Contributions to nephrology. 157:Basel: Karger; 2007;p. 1–7
  22. Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, et al Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17:1724–1734
  23. Onda K, Ohi H, Tamano M, Ohsawa I, Wakabayashi M, Horikoshi S, et al Hypercomplementemia in adult patients with IgA nephropathy. J Clin Lab Anal. 2007;21:77–84
  24. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61:1475–1485
  25. Kriz W, Kretzler M, Nagata M, Provoost AP, Shirato I, Uiker S, et al A frequent pathway to glomerulosclerosis: detection of tuft architecture-podocyte damage-segmental sclerosis. Kidney Blood Press Res. 1996;18:245–253
  26. Hishiki T, Shirato I, Takahashi Y, Funabiki K, Horikoshi S, Tomino Y. Podocyte injury predicts prognosis in patients with IgA nephropathy using a small amount of renal biopsy tissue. Kidney Blood Press Res. 2001;24:99–104
  27. Sakamoto-Ihara T, Suzuki Y, Kurusu M, Yamashita M, Horikoshi S, Tomino Y. Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy. Inflamm Res. 2007;56:421–427
  28. Yamaji K, Kurusu A, Okamoto M, Sekiguchi Y, Horikoshi S, Tomino Y. Effect of educational hospitalization on chronic kidney disease (CKD) patients. Clin Nephrol. 2007;68:401–404
  29. Kobayasi T, Yamaji K, Takeda Y, Maiguma M, Omote K, Sekiguchi Y, et al Efficacy of educational short-term hospitalization in patients with chronic kidney disease (CKD): second report. Nephrology Frontier. 2011;10:94–98
  30. Tomino Y, Kawamura T, Kimura K, Endoh M, Hosoya T, Horikoshi S, et al Antiproteinuric effect of olmesartan in patients with IgA nephropathy. J Nephrol. 2009;22:224–231
  31. Hotta S, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al Tonsillectomy and steroid pulse therapy significantly impact clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–743
  32. Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460–466

PII: S1878-3317(11)00157-4

doi: 10.1016/j.jecm.2011.11.003

Journal of Experimental & Clinical Medicine
Volume 4, Issue 1 , Pages 14-19 , February 2012

Article Tools

* Image Usage & Resolution